Palatin Technologies (PTN) Stock Price, News & Analysis

Company Overview

Palatin Technologies, Inc. is a biopharmaceutical company focused on developing medicines that target melanocortin receptors, a group of receptors involved in regulating inflammation, immune responses, metabolism and sexual function. The company’s research programs are designed to address conditions for which targeted therapies may offer an alternative to existing treatments.

Palatin’s most recognized product is Vyleesi (bremelanotide), a melanocortin receptor agonist approved by the U.S. Food and Drug Administration for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women. Palatin developed the therapy and has pursued commercialization through licensing and partnering arrangements.

The company has also developed investigational compounds, including PL8177, a melanocortin-1 receptor agonist studied for inflammatory and immune-related disorders, and PL9643, an investigational treatment evaluated for ocular conditions such as dry eye disease. Palatin is headquartered in Cranbury, New Jersey, and has historically advanced its programs through internal research, clinical development and collaborations with pharmaceutical partners.

Key Stats

• Today's Range: $4.58 to $5.42
• 50-Day Range: $5.11 to $13.36
• 52-Week Range: $4.58 to $31.00
• Volume: 28,085 shs
• Average Volume: 35,310 shs
• Market Capitalization: $8.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.00
• Consensus Rating: Buy

Palatin Technologies Stock Analysis - MarketRank™

Palatin Technologies scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Palatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Palatin Technologies has a consensus price target of $55.00, representing about 1,041.1% upside from its current price of $4.82.

Amount of Analyst Coverage

Palatin Technologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Palatin Technologies has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PTN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palatin Technologies does not currently pay a dividend.

Dividend Growth

Palatin Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.36

News Sentiment

Palatin Technologies has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Palatin Technologies this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for PTN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Palatin Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Palatin Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.10% of the stock of Palatin Technologies is held by insiders.

Percentage Held by Institutions

11.50% of the stock of Palatin Technologies is held by institutions.

Company Calendar

• Last Earnings: 9/28/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:PTN
• CIK: 911216
• Web: palatin.com
• Phone: (609) 495-2200
• Fax: 609-495-2202
• Employees: 25
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Palatin Technologies: $55.00
• High Price Target: $60.00
• Low Price Target: $50.00
• Potential Upside/Downside: +1,041.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.31 million
• Net Margins: N/A
• Pretax Margin: -48.50%
• Return on Equity: -141.40%
• Return on Assets: -58.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.04
• Quick Ratio: 5.04

Sales & Book Value

• Annual Sales: $4.49 million
• Price / Sales: 1.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.95 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 1,780,000
• Free Float: 1,653,000
• Market Cap: $8.58 million
• Optionable: N/A
• Beta: 0.63